drugset / Trial / NCT01484587
A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to assess the safety and tolerability of CNTO 1959 following a single subcutaneous (SC, under the skin) dose administered to Japanese participants with moderate to severe plaque psoriasis.
Timeline
- Start
- 2011-08-22
- Primary completion
- 2013-04-11
- Completion
- 2013-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 10 mg | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | 300 mg | Subcutaneous |